Shares of Gemphire Therapeutics Inc (NASDAQ:GEMP) have received a consensus rating of “Buy” from the seven research firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $22.75.
Several equities research analysts have recently issued reports on GEMP shares. Zacks Investment Research cut shares of Gemphire Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 17th. HC Wainwright lifted their price objective on shares of Gemphire Therapeutics from $22.00 to $28.00 and gave the stock a “buy” rating in a research report on Friday, January 26th. Roth Capital reaffirmed a “buy” rating and set a $30.00 price objective on shares of Gemphire Therapeutics in a research report on Friday, December 22nd. Finally, ValuEngine cut shares of Gemphire Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Thursday, February 8th.
In other news, insider Steven R. Ph.D. Gullans acquired 71,429 shares of the firm’s stock in a transaction dated Thursday, February 8th. The stock was acquired at an average cost of $7.00 per share, with a total value of $500,003.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 34.00% of the stock is currently owned by insiders.
Shares of Gemphire Therapeutics (GEMP) traded up $0.16 during mid-day trading on Wednesday, reaching $6.82. 92,209 shares of the company’s stock traded hands, compared to its average volume of 163,356. The company has a debt-to-equity ratio of 1.00, a current ratio of 4.17 and a quick ratio of 4.17. Gemphire Therapeutics has a 52 week low of $6.07 and a 52 week high of $21.59. The stock has a market cap of $72.52 and a PE ratio of -2.35.
COPYRIGHT VIOLATION WARNING: This story was first published by Ticker Report and is the property of of Ticker Report. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/3224107/brokerages-set-gemphire-therapeutics-inc-gemp-price-target-at-22-75.html.
Gemphire Therapeutics Company Profile
Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.
Receive News & Ratings for Gemphire Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.